ClinicalTrials.gg
RecruitingNCT06613100Updated Jul 31, 2026

Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer

A Phase 1 interventional study of Xaluritamig and GnRH Antagonist in Prostate Cancer, sponsored by Amgen. Recruiting at 9 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Prostatic Neoplasms by Amgen — 4 open to participants now, 7 under way, 2 of them phase 3. Prostatic Neoplasms · Amgen.

Planned enrollment
17th of 21
40 · median 64
Started
2024
with 2 others
Phase 1
9 of 23
3 open now
Registered
19th of 23
by date

Among the 23 studies in Prostatic Neoplasms by Amgen, this one is the 17th largest by planned enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2024, is one of 9 in phase 1, and was the 19th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

4 of the 23 studies in Prostatic Neoplasms by Amgen are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Prostatic Neoplasms by Amgen, or all of them as a file.
02

Study summary

The primary objectives of this study are to evaluate the safety and tolerability of xaluritamig administered as monotherapy or in combination with an oral Gonadotropin-releasing Hormone (GnRH) antagonist in the neoadjuvant setting followed by radical prostatectomy, and to evaluate the feasibility and safety of a radical prostatectomy following xaluritamig administered as monotherapy or in combination with an oral GnRH antagonist in the neoadjuvant setting.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Xaluritamig
  • AMG509
  • Localized Prostate Cancer
  • Prostate Cancer
  • Neoadjuvant Therapy
  • Immunotherapy
  • T-Cell Engager
  • STEAP1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants are eligible to be included in the study only if all the following criteria apply:

  • Participants planned to undergo radical prostatectomy.
  • or cytologically confirmed adenocarcinoma of the prostate at initial , without neuroendocrine differentiation, signet cell, or small cell features. Intermediate- or high-risk localized prostate cancer, defined as:

    • Gleason score of 4+3 or higher AND initial PSA (iPSA) >10 OR
    • Clinically advanced (cT3) on Magnetic Resonance Imaging (MRI) obtained within 3 months prior to screening AND/OR
    • Positive locoregional lymph nodes as detected by prostate-specific membrane antigen-positron emission tomography (PSMA-PET) scans OR ≤ 5 local lymph nodes on MRI can be enrolled.
  • Participants must have undergone a PSMA-PET (CT or MRI) scan within 3 months prior to screening as part of the standard of care (SOC).
  • (ECOG) performance status of 0 to 1.

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Prior treatment for participant's prostate cancer.

    - Exception: Participants intended for enrollment in cohort B may have received an oral GnRH antagonist up to 3 months prior to the start of screening.

  • Any evidence of outside of the surgical resection field identified by conventional imaging or PSMA-PET scans.
  • Confirmed history or current disease or other diseases resulting in permanent or requiring permanent immunosuppressive therapy.
  • Participants with symptoms and/or clinical signs and/or radiographic signs that indicate an acute and/or uncontrolled active systemic infection within 7 days prior to the first dose of study treatment:

    - Participant has known active infection requiring antibiotic treatment. Upon completion of antibiotics and resolution of symptoms, the participant may be considered eligible for the study from an infection standpoint.

  • Recent history of arterial or venous thrombosis (eg, stroke, , pulmonary embolism, or deep vein thrombosis) within 6 and 3 months prior to the first dose of study treatment, respectively. Note: Participants with a history of venous thrombosis must be on stable anti-coagulation.
  • Myocardial infarction and/or symptomatic congestive heart failure ( ≥ class II) within 12 months of first dose of xaluritamig with the exception of ischemia or non-ST segment elevation myocardial infarction controlled with stent placement more than 6 months prior to first dose of xaluritamig.
  • Requirement for chronic systemic therapy unless stopped (with adequate tapering) within 7 days prior to dosing.
  • Currently receiving treatment in another device or drug study, or less than 4 weeks (since ending treatment on another investigational device or drug study[ies]). Other investigational procedures and participation in observational research studies while participating in this study are excluded with the exception of investigational scans.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Cohort A - Xaluritamig

    Xaluritamig will be administered prior to radical prostatectomy.

    Drug: Xaluritamig

  • Experimental
    Cohort B - Xaluritamig with an Oral GnRH Antagonist

    Xaluritamig will be administered prior to radical prostatectomy. Participants will also receive an oral GnRH antagonist continuously up to the time of planned radical prostatectomy.

    Drug: Xaluritamig · Drug: GnRH Antagonist

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants who Experienced Treatment-emergent Adverse Events

    Inclusive of adverse events, serious adverse events, and changes in vital signs and clinical laboratory tests.

    Time frame: Up to 45 months

  2. Number of Participants who Experienced Treatment-related Adverse Events

    Time frame: Up to 28 months

  3. Number of Participants who Received Radical Prostatectomy After Completing Xaluritamig Treatment

    Time frame: Up to 25 months

  4. Number of Participants who Experienced Complications of Radical Prostatectomy According to Clavien-Dindo Classification

    Time frame: Up to 28 months

Secondary outcomes

  1. Change in Prostate-specific Antigen (PSA) Levels from Baseline to End of Xaluritamig Treatment

    Time frame: Up to 25 months

  2. Prostate Imaging-Reporting and Data System (PI-RADS) Score

    Time frame: Up to 25 months

  3. Pathological Complete Response (pCR) Following Radical Prostatectomy

    Time frame: Up to 25 months

  4. Minimal Residual Disease (MRD)

    Time frame: Up to 25 months

  5. Number of Participants who Rise to PSA ≥ 0.2 ng/mL Post-radical Prostatectomy

    Time frame: Up to 45 months

  6. Time to PSA Rise ≥ 0.2 ng/mL Post-radical Prostatectomy

    Time frame: Up to 45 months

  7. Undetectable PSA at SFU

    Time frame: Up to 26 months

  8. PSA Progression-free Survival

    Time frame: Up to 45 months

  9. Maximum Serum Concentration (Cmax) of Xaluritamig

    Time frame: Up to 45 months

  10. Time to Maximum Concentration (Tmax) of Xaluritamig

    Time frame: Up to 45 months

  11. Area Under the Concentration Time Curve (AUC) Over the Dosing Interval

    Time frame: Up to 45 months

  12. Accumulation Following Multiple Dosing

    Time frame: Up to 45 months

  13. Half-life (t1/2) of Xaluritamig

    Time frame: Up to 45 months

07

Study locations

9 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Feb 2027, 26 months after the start.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 26 months is below that.

Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2024
First posted
Sep 25, 2024
StartActual
Nov 25, 2024
Primary completionEst.
Feb 17, 2027
CompletionEst.
Mar 4, 2030
Last update
Jul 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06613100
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Sep 25, 2024
Start date
Nov 25, 2024
Primary completion
Feb 17, 2027 (estimated)
Completion
Mar 4, 2030 (estimated)
Last update
Jul 31, 2026

Study contacts

Amgen Call Center
Contact
medinfo@amgen.com
866-572-6436
MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Xaluritamig

Start the discussion